Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Efavirenz
100%
Neurocognitive Function
100%
HIV-infected Patients
100%
Lopinavir
60%
Hepatitis C Virus
30%
Neurocognitive
20%
Information Processing Speed
20%
Plasma HIV RNA
20%
Hepatitis C Virus Coinfection
20%
Cerebrospinal Fluid
10%
Multivariable
10%
Comorbidity
10%
Central Nervous System
10%
Neurotoxicity
10%
CD4+ T
10%
Serostatus
10%
Antiretroviral
10%
Randomized Clinical Trial
10%
Therapeutic Effect
10%
Antiretroviral Therapy
10%
Executive Function
10%
HIV RNA
10%
Central Nervous System Toxicity
10%
Cognitive Ability
10%
Neurocognitive Testing
10%
Verbal Fluency
10%
Antiviral Drugs
10%
Psychosocial Outcomes
10%
Working Memory
10%
Second-line Therapy
10%
Antiretroviral Therapy Regimens
10%
HIV Antiretroviral Therapy
10%
Severely Ill Patients
10%
Observational Cohort
10%
Cohort-based
10%
Lower Peak
10%
Effect Research
10%
Research Cohorts
10%
HIV RNA Levels
10%
Neurocognitive Complication
10%
Neuroscience
Human Immunodeficiency Virus
100%
Efavirenz
100%
Lopinavir/Ritonavir
60%
Hepatitis C Virus
50%
Information Processing
20%
Blood Plasma
20%
Central Nervous System
10%
Neurotoxicity
10%
T Cell
10%
Cognitive Function
10%
CD4
10%
Antiretroviral Drugs
10%
Central Nervous System Toxicity
10%
Comorbidity
10%
Working Memory
10%
Immunology and Microbiology
Human Immunodeficiency Virus
100%
Hepatitis C Virus
83%
Ribonucleic Acid
50%
Blood Plasma
33%
Central Nervous System
33%
Coinfection
33%
T-Helper Cell
16%
Cerebrospinal Fluid
16%
Acquired Immune Deficiency Syndrome
16%
Working Memory
16%
Comorbidity
16%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Efavirenz
100%
Lopinavir Plus Ritonavir
60%
Hepatitis C Virus
50%
Mixed Infection
20%
Acquired Immune Deficiency Syndrome
10%
Neurotoxicity
10%
Randomized Clinical Trial
10%
Central Nervous System Toxicity
10%
Comorbidity
10%
Psychology
Hepatitis
100%
Information Processing
40%
Neurological System
40%
Comorbidity
20%
Cognitive Function
20%
Working Memory
20%
Cerebrospinal Fluid
20%
Clinical Trial
20%